Iguratimod Combined With Tofacitinib in the Treatment of Rheumatoid Arthritis

Inclusion Criteria: Patients who meet the following inclusion criteria will be eligible to participate in the study: Male or female aged 18-65 years old; Weight not less than 40kg; Since the diagnosis of RA, the course of disease was ≥6 months; Patients who meet RA standards in 1987 and 2010 ; RA patients with moderate to high disease activity (DAS28 > 3.2) at the time of screening; Active RA (≥6 joints swelling [66 joints count]; ≥Tenderness of 6 joints [68 joint counts]; ESR>28 mm/h or C-reactive protein (CRP) >1.0 mg/dL); Poor response or intolerance to at least one DMARD, including csDMARDs, bDMARDs, but not tsDMARDs; Previous use of any JAK inhibitor was discontinued for six months before enrollment; For patients who have used DMARDs, the washout criteria must be met; Written informed consent; Exclusion Criteria: Patients who meet any of the following criteria will be excluded from the study: Pregnant or lactating women; Platelet count < 10^9/L, or white blood cell < 3*10^9/L, or absolute neutrophil count < 1.2*10^9/L, or Hemoglobin < 9 g/dL or hematocrit <30%; According to Cockcroft-Gault, the glomerular filtration rate was ≤40 ml/min. ALT>1.5×ULN, AST>1.5×ULN, Cr>135umol/L; Subjects with serious cardiovascular, renal, hematologic or endocrine diseases; A history of autoimmune rheumatic diseases other than Sjogren's syndrome; Subjects with uncontrolled infection; Subjects receiving live vaccines within 6 weeks prior to study entry; history of alcohol or drug abuse and abstinence for less than 6 months prior to the first use of the study drug; Subjects participating in other clinical study within 3 months prior to study entry; Have a history of malignant tumor; History of recurrent herpes zoster, diffuse herpes zoster; People who are allergic to any of the study drugs; Other conditions in which the investigator deemed the patient inappropriate for trial entry;